What's Going On With Kintara Therapeutics Stock?

Kintara Therapeutics Inc KTRA shares are trading higher Monday after the company was granted FDA fast track designation for REM-001 for the treatment of patients with cutaneous metastatic breast cancer.

REM-001 was studied in four Phase 2/3 clinical trials in patients with cutaneous metastatic breast cancer who had previously received chemotherapy or failed radiation therapy. Clinical efficacy to-date is approximately 80% when measured as complete responses of cutaneous metastatic breast cancer evaluable lesions.

"We believe this designation is a key component of our future clinical and regulatory strategy as we continue to seek funding, in particular grants, to restart REM-001 clinical development as soon as possible," said Robert Hoffman, president and CEO of Kintara.

Kintara Therapeutics is a biopharmaceutical company focused on the development of new solid tumor cancer therapies.

See Also: US Stocks Head For Rough Start To Week As China Protests Become International Concern

KTRA Price Action: Kintara has a 52-week high of $42 and a 52-week low of $3.50.

The stock was up 25.8% at $4.64 at time of publication, according to Benzinga Pro.

Photo: Michal Jarmoluk from Pixabay.